To fully leverage the potential of these endogenous, tumor-specific T cells, we demonstrate that pMHC-targeted retroviruses can be engineered to target antigen-specific CD8 T cells for in vivo delivery of function-enhancing genetic cargos to modify T cell phenotype. Here, CD8A is linked to neoplasm.